COVID-19 UPDATE

TURKS AND CAICOS ISLANDS PHARMACOVIGILANCE PROGRAMME (TPP) – ADVERSE DRUG REACTION REPORT (ADR) FORM

BEGINS

 

NEWS RELEASE

 

TURKS AND CAICOS ISLANDS PHARMACOVIGILANCE PROGRAMME (TPP) – ADVERSE DRUG REACTION REPORT (ADR) FORM

 

The MoHASHS is currently embarking on a Pharmacovigilance Programme entitled the Turks and Caicos Islands Pharmacovigilance Programme (TPP). This is intended to ensure Good Pharmacovigilance Practice (GPvP) within the Turks and Caicos Islands (TCI). GPvP is the minimum standard for monitoring the safety of medicines on sale to the public.

 

Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. It places emphasis on investigating and monitoring Adverse Drug Reactions (ADR) after medicines are approved and marketed in any jurisdiction.

 

The TPP will be coordinated and monitored by the Pharmacy Unit and will serve as the source for suspected ADR reports. The reports will be submitted through a mechanism of spontaneous and proactive reporting by health care professionals and patients. The TPP will also coordinate activities concerned with Substandard and Falsified Medicine activities.

 

The aforementioned reports will be used as information gathering tools intended to be utilised as quality control measures by:

  • Providing science-based recommendations:
    • On the quality, safety and efficacy of medicines.
    • Relevant to the promotion and protection of the public health that involve medicines.
  • Implementing measures for continuously supervising the quality, safety and efficacy of authorised medicines to ensure that their benefits outweigh their risks.
  • Developing best practices for medicines evaluation and supervision in the TCI.

 

The MoHASHS is very committed to patient safety and views this initiative as a very significant step to strengthen the systems and capacities required to improve the effective monitoring of drug/patient safety.

 

For further information on TPP, please contact André Morgan, National Pharmacist at 338-3072.

 

ENDS

Contact

   This email address is being protected from spambots. You need JavaScript enabled to view it.




Keep in Touch

FacebookTwitter